Millions of people taking semaglutide or tirzepatide for weight loss could be losing more than fat. A pharmacovigilance study spanning two decades of FDA safety reports has flagged elevated signals for muscle atrophy among users of both drugs, raising questions about whether standard clinical checks are catching the problem. The findings arrive as prescriptions for GLP-1 receptor agonists continue to climb and as separate trial data paint a conflicting picture of what actually happens to muscle function during rapid, drug-assisted weight loss.
A safety signal hiding in plain sight
The core alarm comes from a disproportionality analysis of the FDA Adverse Event Reporting System, which collects voluntary reports from manufacturers, health professionals, and consumers. Researchers examined two decades of FAERS submissions and found that semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) showed elevated reporting odds for muscle atrophy compared with other drugs in the database. That signal did not appear at the same strength across older GLP-1 receptor agonists, which suggests something specific about the newer, more potent formulations or about the larger patient populations now using them.
A separate pharmacovigilance effort using VigiBase, the World Health Organization’s global safety report database, examined muscle atrophy signals across antidiabetic drug classes and reached a similar directional conclusion. Two independent databases, two consistent flags. Still, the FDA itself warns that its adverse-event system cannot be used to calculate real-world risk or prove that a drug actually caused a reported problem, because of voluntary reporting, duplicate entries, and selection bias. The signal is real in statistical terms, but its clinical meaning is still contested.
Trial substudies complicate the muscle-loss picture
Clinical trials have tried to quantify the problem using DXA body-composition scans, and the results are not straightforward. An exploratory analysis from the STEP 1 trial measured fat mass versus lean mass changes in participants taking semaglutide 2.4 mg for obesity. The DXA substudy from the SURMOUNT-1 trial did the same for tirzepatide over 72 weeks. Both found that a meaningful share of total weight lost came from lean soft tissue rather than fat alone. That ratio has alarmed some clinicians, because lean-mass loss in older or sedentary patients can accelerate frailty, impair balance, and increase the risk of falls.
Yet DXA has a well-known blind spot. Lean mass on a scan includes not just skeletal muscle but also organ tissue, water, and connective tissue. When someone loses a large amount of weight quickly, fluid shifts and organ-mass changes can inflate the apparent muscle loss. A person who diureses several liters of fluid, for example, may look on DXA as though they have lost lean tissue, even if their actual contractile muscle fibers are largely intact.
The French SEMALEAN cohort study tried to get closer to the functional truth. Investigators tracked patients on semaglutide 2.4 mg at baseline, roughly seven months, and 12 months, measuring both body composition and handgrip strength. Contrary to what the DXA numbers alone might predict, grip strength increased over time even as participants lost substantial weight. If true muscle were wasting at a dangerous rate, grip strength would be expected to fall, not rise. Instead, the data suggested that while some lean mass was lost, remaining muscle may have become more efficient or better able to generate force relative to body size.
This is where the tension sits. Adverse-event databases flag atrophy. DXA scans show lean-mass decline. But the one prospective study that measured actual muscle function found improvement. The contradiction points to a measurement gap rather than a settled answer and underscores how different tools can describe different facets of the same biological change.
Grip strength alone may not tell the full story
Handgrip dynamometry is cheap, fast, and widely used in clinical research as a proxy for overall muscle health. It predicts disability and mortality in many populations and is easy to standardize. However, grip strength is dominated by forearm and hand muscles, and it may not reflect what is happening in the lower body, where the largest muscle groups bear the load of walking, climbing stairs, and preventing falls.
Patients who lose weight rapidly on GLP-1 drugs without adding resistance training could plausibly retain or even improve upper-body function while losing power in the quadriceps, glutes, and calves. That selective pattern would slip past a grip-strength test entirely. Someone might squeeze a dynamometer just fine yet struggle to rise from a low chair or carry groceries up a flight of stairs.
Routine clinical measures such as chair-rise time and gait speed are better at detecting lower-limb weakness, and they already appear in geriatric assessments and sarcopenia research. Expanding their use to younger GLP-1 patients, particularly those losing weight at high rates, could catch functional decline that neither DXA nor grip tests reveal. No published trial has yet tested this specific combination of measures in a GLP-1 population, which is itself a gap worth closing.
Open questions and what patients should watch
Several pieces of the puzzle are still missing. Pharmacovigilance signals cannot say how common muscle atrophy is among GLP-1 users, only that it appears in the database more often than expected. Trial substudies are relatively small and may not reflect older or sicker patients now receiving these drugs in everyday practice. Functional testing has been limited, and most protocols have not integrated comprehensive strength and performance assessments alongside imaging and lab markers.
For now, clinicians are left to manage uncertainty. Few experts argue that semaglutide or tirzepatide should be abandoned wholesale; their benefits for obesity, type 2 diabetes, and cardiovascular risk are substantial. The more pragmatic question is how to use them while minimizing the chance of harmful muscle loss, especially in people who already have low reserves of strength.
Patients starting GLP-1 therapy can take several practical steps while the science catches up. Discuss baseline muscle status with a clinician, including any history of falls, difficulty with stairs, or chronic joint pain that limits activity. Simple tests like timed chair stands or short walking assessments can establish a personal reference point before major weight changes occur.
Building resistance exercise into a treatment plan is another protective measure. Even modest programs using bodyweight movements, resistance bands, or light weights two or three times per week can help preserve or increase muscle mass during calorie deficits. Adequate protein intake, spread across meals, also supports muscle maintenance, though specific targets should be individualized based on kidney function and other medical conditions.
Patients and prescribers should also watch for functional red flags: new difficulty rising from a chair, slowing walking speed, unsteadiness on stairs, or fatigue that makes daily tasks harder despite weight loss. These changes may justify adjusting the drug dose, adding structured physical therapy, or reassessing whether the pace of weight loss is appropriate.
The emerging evidence does not yet settle whether GLP-1 drugs directly damage muscle or whether observed changes simply reflect the biology of rapid weight loss. What it does show is that muscle health cannot be assumed in the rush to shed pounds. As semaglutide and tirzepatide move into broader and younger populations, the next generation of studies will need to look beyond the scale and the DXA scanner to capture what matters most: whether people remain strong enough to live the lives they want as the weight comes off.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
